Role of integrase inhibitors in the treatment of HIV disease

Author: Palmisano, Lucia

Source: Expert Review of Anti-Infective Therapy, Volume 5, Number 1, February 2007 , pp. 67-75(9)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

The introduction of highly active antiretroviral therapy (HAART) has produced a dramatic reduction in HIV-related mortality and morbidity among populations with widespread access to drugs. However, the increase in mutated HIV strains with reduced susceptibility to antiretroviral agents and the emergence of HAART-related side effects make it necessary to develop novel compounds characterized by activity against resistant viruses, a high genetic barrier to resistance and favorable pharmacokinetic and toxicity profiles. Integrase is a key enzyme in the life cycle of HIV and has represented an appealing target of antiretroviral therapy for several years. In 2006, after more than a decade of advances, pitfalls and disappointments, large clinical trials with integrase inhibitors in HIV-positive subjects have eventually begun.

Keywords: antiviral resistance; HAART; HIV infection; HIV RNA; integrase; integrase inhibitors

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14787210.5.1.67

Publication date: 2007-02-01

More about this publication?

Expert Review of Anti-infective Therapy provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites